The aim of this study was to assess the patients' use of inhaled short acting bronchodilators as rescue therapy during a 4-week study period. In this study an electronic metered-dose inhaler compliance monitor (MDI-CM) was used to measure the time and date of actuations of the device and this information was then compared with the patients' self reporting diary card (DC). Salbutamol canisters were used in the compliance monitor. The study was approved by the local ethics committee, and written informed consent was obtained from all patients. Patients aged 18 years and over who were either receiving, or in the investigators opinion required, inhaled salbutamol on a PRN basis were enrolled for a 4-week monitoring phase during which all rescue salbutamol used was obtained from the MDI-CM.
(MDI-CM) was used to measure the time and date of actuations of the device and this information was then compared with the patients' self reporting diary card (DC). Salbutamol canisters were used in the compliance monitor. The study was approved by the local ethics committee, and written informed consent was obtained from all patients. Patients aged 18 years and over who were either receiving, or in the investigators opinion required, inhaled salbutamol on a PRN basis were enrolled for a 4-week monitoring phase during which all rescue salbutamol used was obtained from the MDI-CM.
Patients were recording their use of salbutamol in the DC each morning and evening. There was a 2-week follow-up period following completion of the monitoring phase or withdrawal from the study. Forty-four patients were enrolled and 35 patients completed the study. The mean age (range) was 43 (20-76) 
Introduction
In clinical studies investigating the efficiency of prophylactic asthma therapy it is common practice to assess the patients' use of inhaled bronchodilators as rescue therapy and the data obtained are used as a measurement of efficacy. The quality of this data depends on the accuracy of the patients' self-reporting of bronchodilator use which is usually in the form of a diary card rather than objective measurement.
There are various ways to measure compliance, like measuring the drug in the blood or saliva (l-3) measuring the inhaled drug in the urine (4,5), or using electromechanical counters for various inhaler devices (6-10).
In this study an electronic metered dose inhaler (MDI) compliance monitor (CM) was used to measure the time and date of actuations of the device and this information was then compared with the self-reported diary card (DC). The primary objective of the study was to compare patients' self-reporting of PRN salbutamol use on a daily diary card with actual use as recorded by the MD1 compliance monitor, but the secondary objective was to gain a greater understanding of the functionality of the MDI-CM in patient use. Salbutamol canisters were used in the MDI-CM as this drug is widely used by asthma sufferers on a PRN basis.
Patients and Methods
The study was a single centre open study and patients first entered a 4 week monitoring phase. During this time all rescue salbutamol used was supplied from the MDI-CM, which was tested for validation.
There was a 2 week follow-up period for any patient with an unresolved adverse event following completion of the monitoring phase or withdrawal from the study. Patients were told that MDI-CM contained a 'counter' but not that all actuations would be date and time stamped.
After receiving ethics committee's approval adult patients with airways obstruction fulfiling the following inclusion criteria were asked to participate in the study: (a) patients aged 18 years and over, able and willing to give written informed consent; (b) patients who were receiving or in the investigators opinion required inhaled salbutamol on a PRN basis via a pressurized metered dose inhaler; (c) patients who were able to understand and complete a daily diary card to record the number of puffs of inhaled salbutamol used each day and at night and (d) patients who were able to correctly use a metered dose inhaler as assessed by the investigators.
The following patients were excluded from the study: (a) females who were pregnant or lactating or who were likely to become pregnant during the study (these were excluded as a precaution, however, females of child bearing potential were included if in the investigators opinion they were taking adequate contraceptives);
(b) patients with evidence of alcohol or drug abuse; (c) patients with hypersensitivity to salbutamol and (d) patients who were previously entered into the study.
Forty-four patients were enrolled into the study, out of which nine patients either did not return the diary card or compliance monitor, so data was evaluable for 35 patients. Nineteen patients were male and 25 female with mean age 43 (20-76) years and mean FEV, 2.2 (0.7-4.0) 1.
Results
Patients fell into three groups. (Fig. 1) .
Gvoup 2
Patients [mean age 41 (22-74) years, mean FEV, 2.01(0.8-3.4) 1 and M:F ratio 1: l] who used rescue salbutamol for acute relief but whose DC and MDI-CM recordings did not correlate, 1 l/35 (3 1.4%) (Fig. 2) .
Gvoup 3
Patients [mean age 52 (30-75) years, mean FEV, 2.5 (2.0-3.0) 1 and M:F ratio 5: l] whose use of rescue salbutamol was inappropriate or erratic according to the MDI-CM but whose DC indicated good compliance, 6/35 (17.2%) (Fig. 3) . One patient dumped 114 actuations of MDI-CM 2 days prior to the clinic visit, although the DC of that patient showed regular entries of the use of his inhaled salbutamol; another patient kept neat and regular entries of inhaled salbutamol on DC but MDI-CM did not show the use of a single actuation. There were more discrepancies between the recorded use of inhaler on DC and MDI-CM at night compared to the day (Table 1) . 
Discussion
Common measures used to assess compliance with asthma medications include direct measures (1 l), which confirm the use of medication by assaying it in the blood (1,2), urine (4,5), or saliva (3). Indirect measures can be used with varying degrees of reliability, by the use of clinical judgment, self report on a diary card and electronic monitors (6-10).
We used pressurized study inhalers fitted with compliance monitors. These were electronic devices containing a microchip that recorded the use of inhaler throughout the trial period. They were shower proof and had a battery life of 18 months. The inhaler was able to withstand X-rays as used for security checks at airports. The MD1 compliance monitor had undergone validation testing. Eight volunteers were asked to use a total of 16 MDI-CM each, over a period of 1 month, on varying dosing schedules. The volunteers also kept daily diaries to note the number of doses taken and the time at which they were taken. The diary and compliance monitor recordings were compared. Validation testing showed the compliance monitors recorded to within +2 readings/100 (no recordings were missed) and the time of the recordings fell within the pre-defined limit for accuracy ( i 5 minutes over 1 month period).
Although patients were told that there was a counter inside the inhaler, they were not aware that it could count the date, time and number of actuations. At the end of the trial all study medication was collected and the data was down loaded onto a computer.
Recorded use of rescue bronchodilator is frequently used as an indicator of efficacy for new anti-asthma therapies, and we conclude that, this study comparing electronic monitoring and 'remembered' rescue salbutamol use highlights the potential errors that can occur without accurate recording systems.
While half the population studied showed reasonable correlation between diary card and compliance monitor recordings, the diary card data from the other half did not give an accurate indication of rescue salbutamol usage.
